Zeo ScientifiX, Inc. (ZEOX) stock
ZEOXOTCBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Apr 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$0.91+0.00 (+0.15%)
Close on Oct 19, 2026Market cap $7.08MP/E –Yield –
Zeo ScientifiX operating margin
Operating margin is operating income as a percentage of revenue.
Zeo ScientifiX's operating margin for the twelve months ending Apr 30, 2026 was -59.1%. For fiscal 2025 it was -103.6%, against -115.1% the year before. The highest annual figure on record is -103.6% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -103.6% | +11.5 |
| FY2024 | Oct 31, 2024 | -115.1% | +33.4 |
| FY2023 | Oct 31, 2023 | -148.5% | −12.3 |
| FY2022 | Oct 31, 2022 | -136.2% | +91.4 |
| FY2021 | Oct 31, 2021 | -227.7% | +179.4 |
| FY2020 | Oct 31, 2020 | -407.0% | −302.7 |
| FY2019 | Oct 31, 2019 | -104.4% | +257.5 |
| FY2018 | Oct 31, 2018 | -361.8% | +1154.6 |
| FY2017 | Oct 31, 2017 | -1516.5% | −952.2 |
| FY2016 | Oct 31, 2016 | -564.3% | −60.1 |
| FY2015 | Oct 31, 2015 | -504.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | -19.8% | +101.5 |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | -60.7% | +54.2 |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | -40.4% | +97.9 |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | -158.6% | −57.9 |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | -121.3% | −34.7 |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | -115.0% | +3.5 |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -138.3% | +82.1 |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | -100.7% | +60.5 |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | -86.6% | −14.1 |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | -118.4% | −15.8 |
| Q4 FY2022CQ3 2022 | Oct 31, 2022 | -220.4% | −163.2 |
| Q3 FY2022CQ2 2022 | Jul 31, 2022 | -161.2% | −59.4 |
| Q2 FY2022CQ1 2022 | Apr 30, 2022 | -72.5% | +450.9 |
| Q1 FY2022CQ4 2021 | Jan 31, 2022 | -102.6% | +581.1 |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | -57.2% | +165.8 |
| Q3 FY2021CQ2 2021 | Jul 31, 2021 | -101.8% | −3.0 |
| Q4 FY2020CQ3 2020 | Oct 31, 2020 | -523.4% | −402.1 |
| Q3 FY2020CQ2 2020 | Jul 31, 2020 | -683.8% | −625.2 |
| Q2 FY2020CQ1 2020 | Apr 30, 2020 | -222.9% | −54.3 |
| Q1 FY2020CQ4 2019 | Jan 31, 2020 | -98.8% | +47.4 |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | -121.4% | +2423.6 |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | -58.6% | +40.7 |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | -168.6% | +173.1 |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | -146.2% | +394.8 |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | -2544.9% | −686.5 |
| Q1 FY2018CQ4 2017 | Jan 31, 2018 | -99.3% | +724812.3 |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | -341.7% | +992.2 |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | -541.0% | +119.2 |
| Q2 FY2017CQ1 2017 | Apr 30, 2017 | -1858.4% | −1474.2 |
| Q1 FY2017CQ4 2016 | Jan 31, 2017 | -724911.6% | −724589.0 |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | -1333.9% | −1053.5 |
| Q3 FY2016CQ2 2016 | Jul 31, 2016 | -660.1% | +533.5 |
| Q2 FY2016CQ1 2016 | Apr 30, 2016 | -384.2% | – |
| Q1 FY2016CQ4 2015 | Jan 31, 2016 | -322.7% | – |
| Q4 FY2015CQ3 2015 | Oct 31, 2015 | -280.4% | – |
| Q3 FY2015CQ2 2015 | Jul 31, 2015 | -1193.7% | – |
See a number that looks wrong?